<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092074</url>
  </required_header>
  <id_info>
    <org_study_id>202109016RIND</org_study_id>
    <nct_id>NCT05092074</nct_id>
  </id_info>
  <brief_title>Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection</brief_title>
  <official_title>Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to assess the effectiveness and safety of&#xD;
      sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks in hepatitis C virus&#xD;
      (HCV)-infected patients who fail to prior NS5A-containing DAA regimens and HCV genotype 1a&#xD;
      and 3 patients who fail to prior non-NS5A-containing DAA regimen in Taiwan on a basis of a&#xD;
      multicenter observational study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is a global health problem and it is estimated that about&#xD;
      71 million people are HCV carriers worldwide. Based one the excellent efficacy and safety,&#xD;
      interferon (IFN)-free direct-acting antiviral agents (DAAs) have become the standard of care&#xD;
      (SOC) for the care of HCV. Currently, about 10 different DAA regimens have been approved by&#xD;
      FDA and EMA for the treatment of HCV, the sustained virologic response (SVR) rates are&#xD;
      generally more than 95% by these treatment.&#xD;
&#xD;
      Despite the efficacy and safety are excellent in patients receiving DAAs for HCV, about 1%-5%&#xD;
      of these patients fail to successfully clear virus by DAA treatment. Retreating patients who&#xD;
      fail to respond to DAAs with more potent DAAs would be of paramount importance for treating&#xD;
      physicians and patients. Even since 2017, an estimated of 110,000 to 120,000 viremic patients&#xD;
      in Taiwan have received governmental reimbursement with DAA treatment. Based on a recent&#xD;
      report from National Hepatitis C Program (NHCP) office, about 2% of subjects in Taiwan have&#xD;
      virologic failures to DAA treatment, which implies that about 2,200 to 2,400 HCV-infected&#xD;
      patients remain viremic with the currently approved first-line DAA therapies. Furthermore,&#xD;
      the majority of them have been treated with HCV non-structural 5A (NS5A)-based DAA regimens.&#xD;
      Sofosbuvir/velpatasvir/voxilaprevir, a pangenotypic DAA regimen, serves as a rescue therapy&#xD;
      for HCV patients who do not respond to first-line DAA treatment. The phase 3 POLARIS-1 trial&#xD;
      which retreated HCV patients who failed to respond to NS5A-containing DAAs with SOF/VEL/VOX&#xD;
      for 12 weeks revealed that the SVR12 rate was 96%. Among patients without cirrhosis and with&#xD;
      compensated cirrhosis, the SVR12 rates were 99% and 93%, respectively. In addition, the phase&#xD;
      3 POLARIS-4 trial which retreated HCV genotype 1a and 3 patients who failed to respond to&#xD;
      non-NS5A-containing DAAs with SOF/VEL/VOC for 12 weeks in HCV revealed that the SVR12 rates&#xD;
      were 98% and 94%, respectively. Because all patients enrolled in the POLARIS-1 and POLARIS-4&#xD;
      trials who failed to prior genotype-specific DAA regimens, data regarding the effectiveness&#xD;
      and safety of SOF/VEL/VOX for patients who failed to prior pangenotypic DAA regimens remain&#xD;
      elusive. Two small-scale real-world studies assessing the performance of SOF/VEL/VOX for 12&#xD;
      weeks in patients who failed to pangenotypic SOF/VEL or glecaprevir/pibrentasvir (GLE/PIB)&#xD;
      revealed that SVR12 rates were 100% and 94%. Nonetheless, two real-world studies in Western&#xD;
      countries showed that the SVR12 rates of SOF/VEL/VOX for 12 weeks ranged from 95%-96% for HCV&#xD;
      patients who failed to prior DAA therapies.&#xD;
&#xD;
      Based on the approval of governmental reimbursement of SOF/VEL/VOX retreatment for HCV&#xD;
      genotype 1-6 patients who fail to prior NS5A-containing DAA regimens and HCV genotype 1a and&#xD;
      3 patients who fail to prior non-NS5A-containing DAA regimen on September 1, 2021 in Taiwan,&#xD;
      the investigators aim to conduct a multicenter observational study to assess the real-world&#xD;
      effectiveness and safety of SOF/VEL/VOX for 12 weeks in these patients to provide a powerful&#xD;
      evidence to optimize the clinical practice in Taiwan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR)</measure>
    <time_frame>A total of 24 weeks after the initiation of treatment (drug treatment for 12 weeks and off-treatment follow-up for additional 12 weeks)</time_frame>
    <description>Number and percentage of participants who have undetectable serum level of HCV RNA at off-treatment week 12</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <condition>Treatment Side Effects</condition>
  <condition>Adherence, Treatment</condition>
  <condition>Effect of Drug</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vosevi 400/100/100 Oral Tablet</intervention_name>
    <description>Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. 5 mL of whole blood to detect the HCV viral resistance profiles (NS3 and NS5A regions)&#xD;
           in all participants before SOF/VEL/VOX treatment&#xD;
&#xD;
        2. 5 mL of whole blood to detect the HCV viral resistance profiles (NS3 and NS5A regions)&#xD;
           in participants who fail to respond to SOF/VEL/VOX treatment after off-therapy 12 weeks&#xD;
           of observation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C virus-infected patients who are aged 20 years or more and who are not&#xD;
        responded to a prior course of NA5A-containing DAA regimen (all viral genotypes) or to a&#xD;
        prior course of non-NS5A-containing DAA regimen (viral genotype 1a or 3). Patients should&#xD;
        have compensated liver diseases, and should not take co-medications which are&#xD;
        contraindicated for use in the presence of SOF/VEL/VOX.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis C virus (HCV) infection, defined as the presence of HCV RNA for ≥ 6&#xD;
             months&#xD;
&#xD;
          -  Age ≥ 20 years&#xD;
&#xD;
          -  Patients with any HCV genotype (genotype 1-6 or indeterminate genotype) who failed to&#xD;
             NS5A-containing DAA regimen or patients with HCV genotype 1a or 3 who failed to&#xD;
             non-NS5A-containing DAA regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Patients who receive concomitant medications which are contraindicated for&#xD;
             SOF/VEL/VOX, and who decline to stop or switch contraindicated concomitant medications&#xD;
&#xD;
          -  Patients who receive therapeutic vaccination or other investigational agents for HCV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-Hua Liu, MD</last_name>
    <phone>+886-223123456</phone>
    <phone_ext>63572</phone_ext>
    <email>jacque_liu@mail2000.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Medical University Beigang Hospital</name>
      <address>
        <city>Beigang</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke-Jhang Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Wen Su, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pei-Yuan Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ditmanson Medical Foundation Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Yi Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Po-Yueh Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Martin De Porres Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Chu Lo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jow-Jyh Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yang Ming Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Sheng Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</name>
      <address>
        <city>Dalin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo-Chih Tseng, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Chi-Wei Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Jen Fang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center, Liouying</name>
      <address>
        <city>Liuying</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Jou Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pei-Lun Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fu Jen Catholic University Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Yang Chang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fu-Jen Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Yuan Peng, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hsueh-Chou Lai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Chang Tsai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Shun Yang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Chung-Hsin Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Jie Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Hua Liu, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Jen Liu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Horng Kao, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Yu Kao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Chao Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Lueng Shih, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tsai-Yuan Hsieh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Velpatasvir</keyword>
  <keyword>Voxilaprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

